Novartis AG
CRYSTALLINE FORMS OF N-(5-(5-((1R,2S)-2-FLUOROCYCLOPROPYL)-1,2,4-OXADIAZOL-3-YL)-2-METHYLPHENY- L)IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE

Abstract:

Provided are crystalline forms of N-(5{5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl- )imidazo[1,2-a]pyridine-3-carboxamide fumaric acid, in particular Form A and a N-(5{5-((1R,2S)-2-fluorocyclo-propyl)-1,2,4-oxadiazol-3-yl)-2-methy- lphenyl)imidazo[1,2-a]pyridine-3-carboxamide fumaric acid co-crystal. Provided are also the processes for preparation of such crystalline forms. Furthermore, Provided is a pharmaceutical composition comprising said N-(5{5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylp- henyl)imidazo[1,2-a]pyridine-3-carboxamide fumaric acid Form A, or said N-(5-(5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylpheny- l)imidazo[1,2-a]pyridine-3-carboxamide fumaric acid co-crystal, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment and/or prophylaxis of a mast-cell associated disease, a respiratory disease, an inflammatory disorder, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), an autoimmune disorder, a metabolic disease, a fibrosis disease.